Ethyl (E)-hex-2-enoate | CAS:27829-72-7

We serve Ethyl (E)-hex-2-enoate CAS:27829-72-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Ethyl (E)-hex-2-enoate

Chemical Name:Ethyl (E)-hex-2-enoate
CAS.NO:27829-72-7
Synonyms:Ethyl (E)-hex-2-enoate
ETHYL 2-HEXENOATE
Ethyl hex-2-enoate
trans-2-Hexenoic Acid Ethyl Ester
 
Physical and Chemical Properties:
Density 0.9±0.1 g/cm3
Boiling Point 172.6±9.0 °C at 760 mmHg
Melting Point −2 °C(lit.)
Molecular Formula C8H14O2
Molecular Weight 142.196
Flash Point 62.3±6.2 °C
Vapour Pressure 1.3±0.3 mmHg at 25°C
Index of Refraction 1.433
 
Specification:
Appearance:Colorless transparent liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Brivaracetam(CAS:357336-20-0).



Contact us for information like Ethyl (E)-hex-2-enoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,trans-2-Hexenoic Acid Ethyl Ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ETHYL 2-HEXENOATE Use and application,ETHYL 2-HEXENOATE technical grade,usp/ep/jp grade.


Related News: Cost: Hedge prices of thick product lines + self-produced intermediates fluctuate, and sufficient supply of upstream raw materials can significantly promote the production of APIs.3-(S)-(1-Cyano-1,1-diphenylmethyl)-1-tosylpyrrolidine manufacturer In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.3-Iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine supplier In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.3,3'-(5-bromo-1,3-phenylene)dipyridine vendor In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.